Empagliflozin belongs to the group of SGLT2 inhibitors, which are a new class of glucose lowering agents. Through their unique mechanism to reduce sodium and glucose reabsorption through the proximal tubule, SGLT2 inhibitors play an important role in the prevention and treatment of diabetic nephropathy. The study included 8 patients with type 2 diabetes mellitus on empagliflozin therapy. All of them had their first morning urine albumin/creatinine ratios examined at the beginning and at the third month of treatment. The results showed a significant decrease in albuminuria in 6 of the patients by the third month after applying empagliflozin.
Инхибитори на натриево-глюкозния котранспортер 2 – нов клас антидиабетни лекарства за лечение на захарен диабет тип II, Миронова Д., Григоров Е., Белчева В., Дърленска Т.Х., Годишник по болнична фармация, II, 2016, №1, 59-65;
Ролята на SGLT2–инхибитори в превенцията на бъбречната увреда при пациенти със захарен диабет тип 2, Стоянова Л., сп. „Нефрология, диализа, трасплантация”, 2020 г. бр. 2;
AlicicR. ,Neumiller J.,Johnson E., Dieter,B., Tuttle K., Sodium–Glucose Cotransporter 2 Inhibition and Diabetic Kidney Disease,Diabetes 2019 Feb; 68(2): 248-257. https://doi.org/10.2337/dbi18-0007;
Skrtić M, Yang GK, Perkins BA, Soleymanlou N, Lytvyn Y, von Eynatten M, Woerle HJ, Johansen OE, Broedl UC, Hach T, Silverman M, Cherney DZ, Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration, Diabetologia. 2014 Dec;57(12):2599-602. doi: 10.1007/s00125-014-3396-4. Epub 2014 Oct 4;
Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 2015;373:2117-28. [Crossref] [PubMed];
Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med 2016;375:323-34. [Crossref] [PubMed]; 3 15 MacIsaac RJ, Jerums G, Ekinci EI, Cardio-renal protection with empagliflozinAnn Transl Med. 2016 Oct;4(20):409.
